Last Updated: November 20, 2026

Details for Patent: 6,589,552

« Back to Dashboard


Summary for Patent: 6,589,552
Title:Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it
Abstract:The invention provides fenofibrate compositions comprising granulates. The granulates can comprise micronized fenofibrate, inert hydrosoluble carrier particles, hydrophilic polymers, and, optionally, surfactants.
Inventor(s):André Stamm, Pawan Seth
Assignee: Laboratories Fournier SAS
Application Number:US10/126,875
Patent Claim Types:
see list of patent claims
Composition; Formulation; Process; Dosage form;
Patent landscape, scope, and claims:

US Patent 6,589,552: Fenofibrate Formulation Claims, Expiration, and Patent Landscape

US Patent 6,589,552 protects a multiparticulate fenofibrate formulation using micronized fenofibrate, water-soluble carrier particles, and a substantial amount of hydrophilic polymer. The strongest claim scope centers on the combination of:

  • Fenofibrate particles below 20 microns;
  • At least 20% hydrophilic polymer;
  • A fenofibrate-to-polymer ratio of 1:10 to 4:1;
  • Water-soluble carrier particles, commonly lactose;
  • Optional surfactant, particularly sodium lauryl sulfate;
  • Granulation by spraying a suspension onto carrier particles, including fluidized-bed granulation;
  • Defined dissolution performance.

The patent issued in 2003 and its ordinary US patent term has expired. It therefore does not create a current US blocking right, although its claims remain relevant for historical product reconstruction, freedom-to-operate analysis, patent prosecution strategy, and interpretation of related fenofibrate patent families.

What does US Patent 6,589,552 protect?

The patent protects pharmaceutical compositions rather than fenofibrate as a chemical entity. Its claims target an oral delivery system designed to improve dissolution and absorption of poorly water-soluble fenofibrate.

The core formulation requires a granulated composition containing:

Required feature Claim 1 requirement
Active ingredient Fenofibrate
Fenofibrate particle size Below 20 microns
Carrier Inert, hydrosoluble carrier particles
Hydrophilic polymer At least 20% by weight
Fenofibrate/polymer ratio 1:10 to 4:1
Dosage-form limitation Not required in claim 1
Surfactant Optional in claim 1
Dissolution profile Optional in claim 1

The independent claims are claims 1, 31 and 57.

Claim 1 is the broadest independent composition claim. Claim 31 narrows the polymer to polyvinylpyrrolidone and expressly requires a surfactant. Claim 57 requires a hydrophilic polymer and at least one surfactant, with a surfactant-to-polymer ratio of 1:500 to 1:10.

The patent does not claim all micronized fenofibrate products. A product must satisfy the required formulation architecture and quantitative limitations.

How many independent claims does US 6,589,552 have?

The patent has three principal independent composition claims:

  1. Claim 1: fenofibrate, micronized below 20 microns, hydrosoluble carrier particles, at least 20% hydrophilic polymer, and a fenofibrate-to-polymer ratio of 1:10 to 4:1.
  2. Claim 31: the claim 1 architecture with polyvinylpyrrolidone and surfactant.
  3. Claim 57: the claim 1 architecture with surfactant and a surfactant-to-polymer ratio of 1:500 to 1:10.

Claims 2-30 depend from claim 1. Claims 32-55 depend from claim 31. Claim 56 depends from claim 1 and clarifies that the hydrophilic polymer can be a mixture.

The claim set is therefore structured as three overlapping formulation layers:

Claim layer Main limitation
Claim 1 family Broad hydrophilic-polymer formulation
Claim 31 family Polyvinylpyrrolidone plus surfactant
Claim 57 Surfactant-to-polymer ratio

What technical problem does the patent address?

Fenofibrate has low aqueous solubility. Micronization reduces particle size and increases surface area, but micronization alone does not necessarily provide adequate dissolution or consistent bioavailability.

The claimed formulation addresses this problem through several coordinated elements:

  • Micronized active particles;
  • Hydrophilic polymer wetting and dispersion;
  • Water-soluble carrier particles;
  • Optional surfactant-mediated wetting;
  • Granulation that distributes the active and polymer over carrier particles;
  • A dissolution specification designed to demonstrate rapid release.

The specification’s formulation theory is reflected in the claim structure. The patent does not rely solely on particle size. It requires particle size in combination with polymer loading, carrier selection, and, in several claims, surfactant content or dissolution behavior.

What formulations are protected by claims 1 through 30?

Claims 1 through 30 cover a broad family of granulated fenofibrate products.

Fenofibrate particle-size limitations

Claim 1 requires fenofibrate below 20 microns. Claim 2 narrows that limitation to below 10 microns.

The phrase “below 20 μm” is a numerical limitation. A formulation using fenofibrate with a measured particle-size distribution above that threshold may fall outside the claim, depending on the applicable measurement method and whether the claim requires the entire population or a specified distribution parameter. The claims as provided do not state whether the limitation applies to D90, mean diameter, median diameter, or another particle-size metric. That issue would matter in an infringement dispute.

Fenofibrate concentration

The dependent claims provide the following active-content ranges:

Claims Fenofibrate content
Claim 3 5% to 50% by weight
Claim 4 20% to 45% by weight

A formulation with 30% fenofibrate falls within both dependent ranges if all parent-claim elements are present. The ranges do not replace the broader claim 1 limitation. They add narrower concentration requirements.

Hydrophilic-polymer content

The polymer limitations are:

Claims Hydrophilic polymer content
Claim 1 At least 20%
Claim 5 20% to 60%
Claim 6 At least 25%
Claim 7 25% to 45%

The polymer is a central claim element. A product using a low level of polymer, or using a non-hydrophilic excipient that does not meet the claim construction, presents a potentially meaningful design-around route.

Fenofibrate-to-polymer ratio

Claim 1 requires a weight ratio from 1:10 to 4:1. Claim 8 narrows the range to 1:2 to 2:1.

At a 1:1 ratio, a composition falls within both the broad and narrow ratio ranges, assuming the other limitations are satisfied. The ratio is calculated by weight, not by molar amount or volume.

Polymer identity

Claim 9 lists:

  • Polyvinylpyrrolidone;
  • Polyvinyl alcohol;
  • Hydroxypropylcellulose;
  • Hydroxymethylcellulose;
  • Hydroxypropylmethylcellulose;
  • Gelatin;
  • Mixtures of two or more listed polymers.

Claim 10 narrows the polymer to polyvinylpyrrolidone. Claim 56 expressly covers mixtures of hydrophilic polymers.

The Markush structure creates broad chemical coverage, but it also limits the claims to the listed polymers or legally equivalent materials. An alternative polymer not within the listed group could avoid the literal scope of claims 9 and 10, while still potentially implicating claim 1 if it qualifies as a hydrophilic polymer.

What carrier particles are protected?

The carrier particles must be inert and hydrosoluble. The listed materials are:

  • Lactose;
  • Saccharose;
  • Hydrolyzed starch;
  • Mixtures of those materials.

Claims 11 and 12 specify carrier-particle loading:

Claims Carrier content
Claim 11 10% to 80% by weight
Claim 12 20% to 50% by weight

Claims 13 and 14 specify carrier-particle size:

Claims Carrier-particle size
Claim 13 50 to 500 microns
Claim 14 100 to 400 microns

Claims 15 and 16 narrow the carrier to the listed materials and lactose, respectively.

A formulation using a non-water-soluble carrier, a carrier outside the claimed particle-size range, or a carrier not falling within the applicable claim language may avoid particular dependent claims. Claim 1, however, does not itself recite the specific 50-500 micron range or a particular carrier chemistry.

What surfactant formulations are protected?

Claims 17 through 26 add surfactant limitations to the claim 1 family.

The listed surfactants include sodium lauryl sulfate, polysorbates, sodium dioctylsulfosuccinate, lecithin, fatty alcohols, cholesterol, polyoxyethylene derivatives and poloxamers.

The principal quantitative limitations are:

Claims Surfactant limitation
Claim 20 Up to 10% by weight
Claim 21 0.1% to 3% by weight
Claim 22 Surfactant/polymer ratio of 1:500 to 1:10
Claim 23 Surfactant/polymer ratio of 1:100 to 5:100

Claim 19 narrows the surfactant to sodium lauryl sulfate. Claim 26 requires co-micronization of fenofibrate and surfactant.

Claim 31 is particularly important because it combines:

  • Micronized fenofibrate below 20 microns;
  • Hydrosoluble carrier particles;
  • At least 20% polyvinylpyrrolidone;
  • Surfactant up to 10%;
  • Fenofibrate-to-polyvinylpyrrolidone ratio of 1:10 to 4:1.

A product using PVP and sodium lauryl sulfate may therefore fall within several overlapping claim paths.

What dissolution performance is required?

Claims 24, 25, 49 and 50 require the following dissolution profile:

Time Minimum dissolution
5 minutes 10%
10 minutes 20%
20 minutes 50%
30 minutes 75%

The test uses a rotating blade at 75 rpm under the cited European Pharmacopoeia method.

Two dissolution media are specified:

  1. Water containing 2% polysorbate 80; or
  2. Water containing 0.025 M sodium lauryl sulfate.

These are product-performance limitations, not merely formulation-composition limitations. A product can contain the same excipients as the claimed formulation but fall outside claims 24, 25, 49 or 50 if it does not meet the required dissolution thresholds under the specified testing conditions.

The dissolution claims also raise evidentiary issues. Testing would need to address:

  • Apparatus and rotation speed;
  • Dissolution-medium composition;
  • Sampling times;
  • Assay method;
  • Batch-to-batch variation;
  • Whether the claim requires every unit, every batch, or an average result.

Do claims 29 and 30 cover manufacturing methods?

Claims 29 and 30 are dependent composition claims that characterize the granules by the manufacturing process used to make them.

Claim 29 requires spraying a suspension containing fenofibrate and hydrophilic polymer onto inert hydrosoluble carrier particles. Claim 30 narrows the process to fluidized-bed granulation.

These are product-by-process limitations within composition claims, rather than standalone process claims. Their practical scope depends on claim construction. In an infringement analysis, the relevant question would be whether the accused product has the claimed composition and whether the process language limits the claim to products made by the specified method.

The manufacturing limitations create potential design-around opportunities. A product formed by dry granulation, roller compaction, direct compression, solvent evaporation, spray drying or another process may present a noninfringement argument under a narrow interpretation of the process language. That argument would depend on the prosecution history and applicable Federal Circuit precedent.

When did US Patent 6,589,552 expire?

US Patent 6,589,552 was issued on July 8, 2003. Its US term was based on the application’s effective filing and priority dates and expired in approximately 2017, subject to any patent-term adjustment, terminal disclaimer or other recorded term event. The patent is no longer an enforceable US patent right.

The expiry means:

  • Claims 1-57 cannot support a current US infringement action;
  • A generic manufacturer does not need a present-day license under this patent;
  • The patent cannot block a current ANDA approval or commercial launch;
  • The patent remains relevant as prior art against later applications, subject to the applicable prior-art date.

The precise expiration date should be taken from the USPTO Patent Center term-adjustment and maintenance records for the patent. Public patent databases generally identify the patent as expired by the late 2010s.

What was the FDA and Orange Book relevance?

The patent concerns an oral fenofibrate formulation, a product category associated with Tricor and later fenofibrate products. FDA approval and Orange Book listing are separate from patent validity and enforceability.

A patent can be:

  • Listed in the Orange Book;
  • Omitted from the Orange Book;
  • Listed for one strength or dosage form but not another;
  • Relevant to an ANDA certification without being the principal patent covering the active ingredient.

US 6,589,552 should not be treated as a current Orange Book barrier solely because it covers a fenofibrate formulation. Orange Book status must be confirmed through the FDA’s current Approved Drug Products with Therapeutic Equivalence Evaluations database and the relevant reference-listed drug entry. The patent’s expiration independently removes its current blocking effect.

Fenofibrate products have also been approved through different regulatory routes and dosage forms, including tablets, capsules and combination products. The relevant patent certifications depend on the specific reference-listed drug and dosage form.

Which companies challenged fenofibrate exclusivity?

Fenofibrate faced generic competition from multiple manufacturers after FDA approval of abbreviated new drug applications. Companies active in the US fenofibrate market have included Teva, Mylan, Impax, Sandoz, Watson/Actavis and other generic manufacturers, depending on product strength and dosage form.

The major historical patent disputes involving branded fenofibrate products generally focused on patents covering formulation, bioavailability, dosage forms and product-specific delivery characteristics. They did not necessarily involve US 6,589,552 as the only asserted patent.

A Paragraph IV certification against a fenofibrate patent would require the ANDA applicant to allege that the patent is invalid, unenforceable or not infringed. The patent’s expiration means that any historical Paragraph IV significance has ended as a current launch barrier.

How strong was the patent estate?

Claim-strength assessment

Issue Assessment
Breadth of claim 1 Moderate to broad within a defined formulation architecture
Dependence on numerical ranges High
Dependence on excipient identity Moderate
Product-by-process exposure Material for claims 29, 30, 54 and 55
Dissolution limitations Narrow but technically concrete
Design-around potential Moderate to high
Current enforceability None because the patent has expired

The strongest historical protection was the combination of micronized fenofibrate, high hydrophilic-polymer loading and water-soluble carrier particles. The claim set is less powerful against formulations using a different manufacturing route, a different polymer system, no carrier particles, or a substantially different polymer-to-drug ratio.

The patent did not claim:

  • Fenofibrate itself;
  • Micronized fenofibrate as a standalone product;
  • Every tablet or capsule containing fenofibrate;
  • Every formulation using lactose;
  • Every formulation using PVP;
  • Every formulation with rapid dissolution.

It claimed specific combinations of those components and performance characteristics.

How does US 6,589,552 compare with other fenofibrate patents?

The fenofibrate patent landscape has generally divided into five categories:

Patent category Typical protected subject matter
Active-ingredient patents Fenofibrate chemical compound and derivatives
Micronization patents Particle-size reduction and micronized active
Formulation patents Excipients, dissolution, bioavailability and dosage forms
Manufacturing patents Granulation, coating, spray processing and particle engineering
Clinical-use patents Treatment of dyslipidemia and cardiovascular risk

US 6,589,552 falls in the formulation and manufacturing interface. It is narrower than a compound patent but potentially more relevant to a specific commercial product than a general fenofibrate compound disclosure.

Related fenofibrate patents, including patents associated with Fournier and later branded-product owners, should be reviewed as a family rather than in isolation. Patent numbers frequently cited in the historical Tricor landscape include US 6,074,670 and US 6,277,405, but their claim scope, term, listing status and litigation history must be analyzed separately from US 6,589,552.

What generic launch risks existed?

Before expiration, a generic fenofibrate product could face risk if it replicated the claimed combination of:

  • Sub-20-micron fenofibrate;
  • At least 20% PVP or another listed hydrophilic polymer;
  • Lactose or another hydrosoluble carrier;
  • Claimed drug-to-polymer ratio;
  • Sodium lauryl sulfate or another listed surfactant;
  • Spray or fluidized-bed granulation;
  • Claimed dissolution profile.

Potential design-around paths included:

  1. Using a different polymer outside the listed Markush group;
  2. Reducing polymer content below 20%;
  3. Using a fenofibrate-to-polymer ratio outside 1:10 to 4:1;
  4. Eliminating the inert hydrosoluble carrier particles;
  5. Using a different carrier structure;
  6. Avoiding the claimed surfactant ratios;
  7. Using a different granulation process;
  8. Failing the specific dissolution limitations;
  9. Using a dosage form or composition that does not meet all elements of an asserted claim.

Because the patent has expired, these historical strategies no longer create a current US launch requirement.

What geographic coverage does the patent have?

US 6,589,552 provides US-only rights. It does not directly protect products in Europe, Canada, Japan, China or other jurisdictions.

The underlying invention may have been pursued through corresponding foreign applications and regional patent families. Foreign counterparts can have:

  • Different claim amendments;
  • Different expiration dates;
  • Different prosecution histories;
  • Different validity outcomes;
  • Different national-phase status.

A global freedom-to-operate review therefore requires separate analysis of the corresponding European, Canadian, Australian and other national patents. Expiration of the US patent does not establish expiration of every foreign counterpart.

Key Takeaways

  • US 6,589,552 is a formulation patent, not a fenofibrate compound patent.
  • Its core claim requires micronized fenofibrate below 20 microns, hydrosoluble carrier particles, at least 20% hydrophilic polymer and a defined drug-to-polymer ratio.
  • Claims 31 and 57 add important surfactant and polyvinylpyrrolidone limitations.
  • Dependent claims cover lactose carriers, particle-size ranges, sodium lauryl sulfate, co-micronization, dissolution performance and fluidized-bed granulation.
  • The patent’s historical strength came from the combination of formulation elements, not any single excipient.
  • The patent expired in the United States by approximately 2017 and does not present a current US blocking right.
  • Current Orange Book, ANDA, Paragraph IV and generic-launch analysis must focus on unexpired patents and the specific reference-listed fenofibrate product.
  • Foreign counterparts require separate term and legal-status review.

FAQs

Is US 6,589,552 a patent on Tricor?

It is a fenofibrate formulation patent associated with the technical field used by branded fenofibrate products, but the patent does not claim the Tricor brand name or every Tricor formulation.

Does using micronized fenofibrate infringe US 6,589,552?

Micronization alone is insufficient. The relevant claim also requires the specified polymer, carrier particles, quantitative ratios and other limitations.

Does lactose automatically create infringement risk?

No. Lactose is a claimed carrier in dependent claims, but lactose alone does not satisfy the full claim combination.

Is a formulation with polyvinylpyrrolidone covered?

It may be, if it also contains the required micronized fenofibrate, hydrosoluble carrier particles, polymer concentration, drug-to-polymer ratio and, for claim 31, a surfactant.

Can US 6,589,552 block a new generic fenofibrate launch?

No. The US patent has expired. A current launch analysis must identify unexpired patents, FDA exclusivity, applicable Orange Book listings and any separate regulatory barriers.

References

  1. United States Patent and Trademark Office. (2003). U.S. Patent No. 6,589,552, Pharmaceutical compositions containing fenofibrate.
  2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
  3. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations.
  4. United States Patent and Trademark Office. (2024). Patent Center and patent term adjustment records.
  5. United States Code, 35 U.S.C. §§ 154, 156 and 271.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 6,589,552

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,589,552

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France97 00479Jan 17, 1997

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.